Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

SuperSonic Imagine, a leader in ultrasound imaging, has developed a unique technology that offers practitioners and patients a real and unparalleled breakthrough in the diagnosis and follow up of breast, prostate and thyroid cancers, as well as liver diseases.

The flagship Aixplorer® series is a new generation of ultrasound products incorporating UltraFast™ technology that renders images with exceptional definition, contrast and resolution. Aixplorer systems have an innovative imaging technique that enables the elasticity of tissue to be quantified, visualized and analyzed in real-time, in a reproducible and non-invasive manner. This leads to improved diagnostic capabilities and can help reduce the number of unnecessary biopsies. These clinical benefits enable practitioners to have a solution at their disposal to better detect, characterize and classify the various pathologies during a simple ultrasound examination.

Rest assured that we will remain completely focused on the realization of our projects and that we will do our best to ensure that Aixplorer^® series is a global success.

ECR 2016 Symposium - Clinical Innovations Improving Breast Cancer Diagnosis - Prof. Schäfer - Video